| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/11/2010 | WO2010017466A2 Phenobarbital salts; methods of making; and methods of use thereof |
| 02/11/2010 | WO2010017443A2 Anti-beta-2-microglobulin agents and the use thereof |
| 02/11/2010 | WO2010017418A1 Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| 02/11/2010 | WO2010017405A1 Methods and compositions for the treatment of pain |
| 02/11/2010 | WO2010017403A2 Therapeutic compositions, devices and methods for observing treated tissues |
| 02/11/2010 | WO2010017401A1 Bi-1h-benzimidazoles as hepatitis c virus inhibitors |
| 02/11/2010 | WO2010017374A1 Process for preparing azacytidine intermediate |
| 02/11/2010 | WO2010017368A2 Methods and compositions for treating anxiety |
| 02/11/2010 | WO2010017365A1 Wax-based emulsion for the treatment of dry eye conditions |
| 02/11/2010 | WO2010017358A1 Sustained release compositions comprising gums and sugar alcohols |
| 02/11/2010 | WO2010017355A2 Small molecule inhibitors of retroviral assembly and maturation |
| 02/11/2010 | WO2010017350A1 Aminopyridine kinase inhibitors |
| 02/11/2010 | WO2010017343A2 Flupirtine hydrochloride maleic acid cocrystal |
| 02/11/2010 | WO2010017323A1 Novel methylenedioxy phenolic compounds and their use to treat disease |
| 02/11/2010 | WO2010017317A2 Use of mtor inhibitors to enhance t cell immune responses |
| 02/11/2010 | WO2010017312A1 Compositions and methods for treating inflammatory conditions of the bowel |
| 02/11/2010 | WO2010017310A1 Method for the treatment of acne and certain dosage forms thereof |
| 02/11/2010 | WO2010017282A1 Polyurethane-grafted hydrogels |
| 02/11/2010 | WO2010017273A2 Tigecycline formulations |
| 02/11/2010 | WO2010017272A2 Method of treating neurological diseases |
| 02/11/2010 | WO2010017264A2 Photo-crosslinked nucleic acid hydrogels |
| 02/11/2010 | WO2010017260A1 Tripyridyl carboxamide orexin receptor antagonists |
| 02/11/2010 | WO2010017240A2 Aurora kinase modulators and methods of use |
| 02/11/2010 | WO2010017236A1 Pde10 inhibitors and related compositions and methods |
| 02/11/2010 | WO2010017179A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 02/11/2010 | WO2010017163A1 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| 02/11/2010 | WO2010017154A2 Modulation of toll-like receptor 3 expression by antisense oligonucleotides |
| 02/11/2010 | WO2010017152A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 02/11/2010 | WO2010017150A1 Compounds useful as inhibitors of protein kinases |
| 02/11/2010 | WO2010017135A2 Novel forms of eperisone |
| 02/11/2010 | WO2010017132A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 02/11/2010 | WO2010017131A2 Modulation of toll-like receptor 7 expression by antisense oligonucleotides |
| 02/11/2010 | WO2010017122A2 Methods of treating thalassemia |
| 02/11/2010 | WO2010017120A1 Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
| 02/11/2010 | WO2010017105A1 Urotensin ii receptor antagonists |
| 02/11/2010 | WO2010017093A2 Dopamine receptor ligands with enhanced duration of action |
| 02/11/2010 | WO2010017079A1 Oxazole derivatives useful as inhibitors of faah |
| 02/11/2010 | WO2010017060A1 Urea derivatives as antibacterial agents |
| 02/11/2010 | WO2010017055A2 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/11/2010 | WO2010017051A1 Novel phenylamino isonicotinamide compounds |
| 02/11/2010 | WO2010017047A1 Therapeutic compounds |
| 02/11/2010 | WO2010017046A1 Pyrazolo[1,5-a]pyridines as mark inhibitors |
| 02/11/2010 | WO2010017040A1 Diacylglycerol acyltransferase inhibitors |
| 02/11/2010 | WO2010017035A2 Inhibitors of iap |
| 02/11/2010 | WO2010016939A1 Hypoglycemic dihydropyridones |
| 02/11/2010 | WO2010016931A2 Polymorphs of fluticasone furoate and process for preparation thereof |
| 02/11/2010 | WO2010016846A1 Heterocyclic modulators of tgr5 for treatment of disease |
| 02/11/2010 | WO2010016844A1 Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis |
| 02/11/2010 | WO2010016806A1 Vhz for diagnosis and treatment of cancers |
| 02/11/2010 | WO2010016681A2 Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of lxr-alpha |
| 02/11/2010 | WO2010016638A1 Composition containing anti -microrna for treating or preventing solid cancers |
| 02/11/2010 | WO2010016628A1 Conjugated suramin amino compounds for medical conditions |
| 02/11/2010 | WO2010016590A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 02/11/2010 | WO2010016554A1 Cyclic amine compound |
| 02/11/2010 | WO2010016552A1 Therapeutic agent for irritable bowel syndrome |
| 02/11/2010 | WO2010016549A1 Tricyclic compound |
| 02/11/2010 | WO2010016509A1 Stable pharmaceutical composition containing tranexamic acid and ascorbic acid |
| 02/11/2010 | WO2010016490A1 Imidazopyridin-2-on derivative |
| 02/11/2010 | WO2010016044A1 Treatment of retinal degeneration |
| 02/11/2010 | WO2010016043A1 Treatment of retinal degeneration |
| 02/11/2010 | WO2010016042A1 Treatment of retinal degeneration |
| 02/11/2010 | WO2010016011A1 Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells |
| 02/11/2010 | WO2010016005A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 02/11/2010 | WO2010015985A1 Tricyclic alkylaminomethyloxazolidinone derivatives |
| 02/11/2010 | WO2010015972A1 Diazepine and diazocane compounds as mc4 agonists |
| 02/11/2010 | WO2010015965A2 Methods and compositions for treating neuronal damage and modulating transient receptor potential channels |
| 02/11/2010 | WO2010015939A1 Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack |
| 02/11/2010 | WO2010015911A1 Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof |
| 02/11/2010 | WO2010015874A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols |
| 02/11/2010 | WO2010015870A1 Use of dihydralazine for the treatment of diseases related to elevated semicarbazide sensitive amine-oxidase (ssao) activity |
| 02/11/2010 | WO2010015840A1 Osmotic delivery device with modified release |
| 02/11/2010 | WO2010015827A2 Phosphate binding materials and their uses |
| 02/11/2010 | WO2010015818A1 Respiratory disease treatment |
| 02/11/2010 | WO2010015816A2 Treatment of lysosomal storage disorders and other proteostatic diseases |
| 02/11/2010 | WO2010015803A1 Diazaindole derivatives and their use in the inhibition of c-jun n-terminal kinase |
| 02/11/2010 | WO2010015800A1 Chewable formulation comprising alginate, bicarbonate and carbonate |
| 02/11/2010 | WO2010015797A1 Sertraline composition |
| 02/11/2010 | WO2010015794A1 Novel polymorphic forms of tegaserod |
| 02/11/2010 | WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| 02/11/2010 | WO2010015718A1 Treatment of vaginal atrophy in women with tumor pathology risk |
| 02/11/2010 | WO2010015713A1 Progestin-containing drug delivery system |
| 02/11/2010 | WO2010015692A2 Bupropion hydrobromide polymorphs |
| 02/11/2010 | WO2010015688A1 Oral formulations of chemotherapeutic agents |
| 02/11/2010 | WO2010015672A1 Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye |
| 02/11/2010 | WO2010015664A1 Treatment for diabetes in patients inappropriate for metformin therapy |
| 02/11/2010 | WO2010015657A2 New alkoxypyrazoles |
| 02/11/2010 | WO2010015656A2 New alkoxypyrazoles |
| 02/11/2010 | WO2010015655A1 Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists |
| 02/11/2010 | WO2010015653A1 Pyrimidine derivatives as activators of soluble guanylate cyclase |
| 02/11/2010 | WO2010015643A1 New antiviral modified nucleosides |
| 02/11/2010 | WO2010015637A1 New antiviral modified nucleosides |
| 02/11/2010 | WO2010015628A1 Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists |
| 02/11/2010 | WO2010015626A1 Crystalline forms of a pyridine derivative |
| 02/11/2010 | WO2010015617A1 Process for producing carnosol from carnosic acid using hydrogen peroxide or peracids |
| 02/11/2010 | WO2010015613A1 Organic compounds |
| 02/11/2010 | WO2010015590A1 Organotin(iv) complexes with n-acetylcysteine possessing antitumoral activity, process for their production and their use |
| 02/11/2010 | WO2010015589A1 Benzyl-substituted tetracyclic heterocyclic compounds as pde5 inhibitors |
| 02/11/2010 | WO2010015588A1 Benzyl-substituted tetracyclic heterocyclic compounds |
| 02/11/2010 | WO2010015587A1 5-benzyl-1,2,3,6-tetrahydro-4,6-diaza-cyclopenta[c]fluorene compounds and 5-benzyl-1,2,3,6-tetrahydro-4,6-diaza-cyclohepta[c]fluorene compounds |
| 02/11/2010 | WO2010015586A2 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds |